Biomerica (BMRA) to Announce Quarterly Earnings on Thursday

Biomerica (NASDAQ:BMRA) is anticipated to announce its results before the market opens on Thursday, August 27th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $2.2160 million for the quarter.

Biomerica Trading Up 4.3%

Shares of BMRA opened at $1.68 on Tuesday. Biomerica has a 12-month low of $1.45 and a 12-month high of $3.51. The firm has a 50-day moving average price of $1.66 and a 200 day moving average price of $2.00. The firm has a market capitalization of $5.19 million, a P/E ratio of -1.89 and a beta of 0.35.

Analyst Ratings Changes

BMRA has been the topic of a number of analyst reports. Weiss Ratings downgraded shares of Biomerica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, June 5th. Citizens Jmp began coverage on shares of Biomerica in a research note on Tuesday, May 5th. They issued a “mkt outperform” rating and a $9.00 price target for the company. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell” and an average target price of $9.00.

Institutional Trading of Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC raised its stake in Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,925 shares of the company’s stock after buying an additional 6,533 shares during the quarter. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 at the end of the most recent quarter. Institutional investors and hedge funds own 22.28% of the company’s stock.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.